Learning ZoneXpress Leads the Way in Offering MyPlate (MiPlato) Nutrition Tools in Spanish

Michelle Obama emphasizes need for Spanish-language nutrition education

Owatonna, MN (PRWEB) February 16, 2012

Nearly two out of five children in the Hispanic community are overweight or obese, as compared to one in three kids overall – a fact First Lady Michelle Obama pointed out last month in an address promoting MiPlato, the Spanish-language version of the MyPlate nutrition guidelines. And according to the 2010 U.S. Census, more than 35 million U.S. residents speak Spanish at home. These statistics point to the need for Spanish-language materials on nutrition education, a need that Minnesota-based Learning ZoneXpress has been filling since 2005. In fact, in a partnership with the USDA, Learning ZoneXpress was the first company in the United States to offer MiPlato posters. The company also doubled its Spanish-language offerings in 2011.

“Learning ZoneXpress strives to educate all children, families and communities on eating well,” says Melanie Nelson, founder and CEO of Learning ZoneXpress, the leading producer of health and nutrition education materials in the U.S. “We are proud that our Spanish-language versions of MyPlate and other tools are able to meet a growing need for relevant information about nutrition for the Hispanic community.”

Learning ZoneXpress carries more than 50 Spanish-language products that are perfect for the classroom, cafeteria, medical office and more, including:

The company also provides nutrition education tools to Spanish-speaking communities outside of the U.S. The Chilean health organization, Educacion Popular En Salud, recently partnered with Learning ZoneXpress to distribute MiPlato products, and the company looks forward to strong growth throughout Central and South America.

The English-language MyPlate products from Learning ZoneXpress are also in high demand. In the time since LZX partnered with the USDA just over half a year ago – the MyPlate line of products from Learning ZoneXpress have proven to be wildly popular and effective methods for relaying the new guidelines to people of all ages. Currently, seven out of the top 10 best-selling products from Learning ZoneXpress are MyPlate items.

The USDA’s MyPlate nutrition guidelines recommend changes such as making half your plate fruit and vegetables, varying your protein food choices, making at least half your grains whole grains, switching to skim or 1% milk and cutting back on foods high in solid fats, added sugars and salt.

In late January, Michelle Obama spoke to the need for MyPlate resources in the Hispanic population in an announcement that Goya Foods, the largest Hispanic-owned U.S. food company, would also partner with the USDA to promote MiPlato.

“We are thrilled that Goya Foods and other Latino organizations are joining us in supporting the USDA’s MiPlato campaign,” Nelson says. “It’s crucial that the Hispanic community has access to nutrition education, and the more organizations behind the effort, the better.”

Learning ZoneXpress’s MyPlate, MiPlato and other educational products range from $4.95 - $499.95 and are available at LearningZoneXpress.com.

Learning ZoneXpress, based in Owatonna, Minn., is a leading source of “edu-taining” and award-winning teaching tools. Its mission is to help improve the health and vitality of children by providing relevant, creative and affordable learning tools about life skills, healthy behaviors and nutrition. Learning ZoneXpress offers a wide variety of learning aids and affordable education DVDs, posters, games, lesson plans, and PowerPoint presentations.

For more information about Learning ZoneXpress products, visit http://www.learningzonexpress.com or call Toni Gnasdoskey at 888-455-7003.

###

Toni Gnasdoskey
Learning ZoneXpress
8004557003
Email Information

View post:
Learning ZoneXpress Leads the Way in Offering MyPlate (MiPlato) Nutrition Tools in Spanish

Nutrition Labeling Law Lowered Nutrition, Improved Taste

Prof Christine Moorman's researches "unintended nutrition consequences"

February 16, 2012

DURHAM, N.C. -- In the nearly two decades since regulations required food products to contain a "Nutrition Facts" label, the overall nutritional quality of branded food products in supermarkets has decreased while the taste of these same products has improved, according to researchers at Duke University and the University of Maryland.

Among those foods that did improve their nutrition, "junk foods" or low-health products increased their nutrition more than healthier options. And among companies, those with smaller brands or fewer existing brands were more likely to make improvements to the nutrition of their products. 

These findings from researchers at Duke's Fuqua School of Business and Maryland's Robert H. Smith School of Business will be published in a forthcoming edition of the journal Marketing Science.

The research was conducted through two studies of food products before and after the nutrition labeling regulations. The first study investigated food products in 30 product categories -- some required by the Nutrition Labeling and Education Act (NLEA) of 1993 to feature nutrition labels such as foods in supermarkets, and some not required to feature nutrition labels such as similar foods in restaurants.

The second study used a sample of brands from Consumer Reports to examine brand nutrition and taste for a smaller set of categories before and after the NLEA.

"We think the main reason for our results is that consumers find taste more important than nutrition, as indicated by consumption trends during this time showing increased consumption for added fats and sugars as well as a 100 percent increase in calories from snacking," said Christine Moorman, professor of business administration at Fuqua.
"And since nutrition is perceived to be negatively correlated with taste, we believe many companies decided to reduce the nutritional value of their food products after the passage of the NLEA," Moorman said. "Since nutrition labels were generally not present before the NLEA, consumers would not be aware of these changes, only that the product competed well on taste."

The changes are what Moorman and her co-authors call "unintended nutrition consequences."

The NLEA sought to eliminate untruthful nutritional claims and to improve consumers' ability to find nutrition information at the point of sale. Manufacturers are required to display a label of nutrition facts with standardized information on all nutrients, recommended daily values and an ingredient list.

Claims of health benefits on food packaging are also regulated for truthful content. Prior to adoption of the NLEA, most food products did not commonly disclose nutrition information, which made comparisons within and across food categories difficult for consumers.

"It would be reasonable to assume the NLEA's required labels would help consumers find healthful foods and stimulate competition to improve brand nutrition," said Rosellina Ferraro, assistant professor of marketing at Smith. "Our research indicates food producers were reluctant to improve nutrition on the belief that consumers will perceive better nutrition as a taste tradeoff." 

While the nutritional value of most foods declined in the years following the NLEA, some foods have improved nutrition. The researchers found brands in low-health categories (e.g., potato chips) and small-portion categories (e.g., peanut butter) improved nutrition more than brands competing in high-health categories (e.g., bread) or large-portion categories (e.g., frozen dinners).

Likewise, smaller companies in a food category and those companies with fewer existing brands were more likely to improve nutrition.

"This makes sense because companies may have hoped to grab the attention of health-conscious consumers while many of their large counterparts hesitated for fear of negative consumer reactions," Moorman said.

"In some significant ways, the NLEA has brought about results that are nearly the opposite of what was intended," Moorman said. "The policy lesson is that well-meaning regulation that forces the disclosure of information on an attribute (e.g., nutrition) that is less important than another attribute (e.g., taste) is not likely to encourage companies to compete on the disclosed attribute. Instead they will compete on the most important attribute."

Therefore, the ongoing challenge for food producers, policy makers and public health advocates is to increase the value consumers place on nutrition and to reduce the perceived nutrition-taste tradeoff, the authors argue.

The study was supported by grants from the National Science Foundation and the Marketing Science Institute.

More here:
Nutrition Labeling Law Lowered Nutrition, Improved Taste

Future UK Microbiology Testing Market Outlook

NEW YORK, Feb. 16, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Future UK Microbiology Testing Market Outlook

http://www.reportlinker.com/p0771119/Future-UK-Microbiology-Testing-Market-Outlook.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

Highlights

Comprehensive 978-page analysis of the UK microbiology testing market. Major issues pertaining to the UK microbiology laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. Current scientific views on the definition, epidemiology, and etiology of major infectious diseases and microorganisms. Ten-year test volume and sales forecasts for nearly 80 microbiology tests performed in UK hospitals, blood banks, public health and commercial laboratories. Instrumentation technologies and feature comparison of leading analyzers. Sales and market shares of leading suppliers. Emerging diagnostic technologies and their potential market applications. Product development opportunities. Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Business opportunities and strategic recommendations for suppliers.

Contains 978 pages and 159 tables

IntroductionWorldwide Market and Technology OverviewA. Major Infectious Disease Tests1. AIDSa. Background0 Structure and Composition0 Classification0 Origin of AIDS0 Animal Lentivirus Systems0 Virus Receptos0 HIV Infections in Humans- Pathogenesis & Pathology: Overview ofHIV Infection Course0 CD4T Lymphocytes and Memory Cells0 Monocytes and Macrophages0 Lymphoid Organs0 Neural Cells0 Viral Coinfections- Clinical Findings0 Plasma Viral Load0 Pediatric AIDS- Neurologic Disease- Opportunistic Infections- Cancer0 Immunity- Virus Isolation- Serology- Detection of Viral NucleicAcid and Antigens0 Infectivity0 Epidemiology- Worldwide Spread of AIDS- United States- Routes of Transmission

b. Diagnostic Tests

0 Laboratory Diagnosis

- Enzyme Immunoassay Interpretation

- Specific, Sensitivity, and Predictive

Value of Enzyme Immunoassays

0 Competition Assays

0 Western Blot Technique

0 Immuno-Fluorescence Assay (IFA)

0 Radioimmunoprecipitation

0 HIV-1/HIV-2 Combination Testing

0 Methods of HIV-Antigen Detection

0 Antigen Assays and Blood Screening

0 Urine Tests

0 Immunopathogenic Mechanism of HIV Infection

0 DNA Probes

- Overview

- Quantitative Polymerase Chain Reaction

- In Situ PCR

- Needed Improvements

0 Viral Load/Drug Resistance Testing

0 Genotype and Phenotype Testing

0 Blood Banking Consideration

c. Vaccines and Drugs

- Antiviral Drugs

- Vaccines Against HIV

0 Transmission of HIV in Blood Products

0 HIV Transmission in Transplant and

Artificial Insemination Recipients

2. Adenovirus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

d. Adeno-Associated Viruses(AAV)

3. Aeromonas

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

4. Anthrax/Bacillus Anthracis

a. Background

b. Diagnostic Testsc. Vaccines and Drugs5. Arbovirusesa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs6. Babesiosisa. Background7. Bacillary Epithelioid Angiomatosis (BEA)And Other Bartonella (Rochalimaea)a. Backgroundb. Diagnostic Testsc. Vaccines and Drugs8. Blastocystis Hominisa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs9. Brucellaa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs10. Campylobactera. Backgroundb. Diagnostic Tests0 Identification from Culturec. Vaccines and Drugs11. Candidaa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs12. Chagas Diseasea. Background13. Chancroida. Backgroundb. Diagnostic Testsc. Vaccines and Drugs14. Chlamydiaa. Background0 Chlamydia Psittaci

0 Chlamydia Pneumoniae

0 Chlamydia Trachomatis

b. Diagnostic Tests

c. Vaccines and Drugs

15. Clostridium Difficile

a. Background

0 Pediatric Infections

0 Epidemiology

b. Diagnostic Tests

0 Counterimmunoelectrophoresis

0 Fluorescent-Antibody Assays

0 Poloymerase Chain Reactions

c. Drugs and Vaccines

16. Coronaviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

17. Coxsackieviruses

a. Background

0 Herpangina

0 Hand-foot-and-mouth syndrome

0 Hepidemic Conjuctivitis

0 Pharingitis

0 Epidemic Pleurodynia

0 Myodarditis,Pericarditis

0 Overwhelming Infection of the Newborn

0 Acute Aseptic Meningitis

0 Undifferentiated Febrile Illness

0 Fever with upper respiratory infection

0 Encephalitis

0 Asymptomatic Infection

b. Diagnostic Tests

c. Vaccines and Drugs

18. Creutzfeldt-Jakob's Disease

a. Background

0 Blood Transmission

b. Diagnostic Tests

0 Major Commercial and Academic Players

- Bayer

- Disease Sciences/Bio Tec Global- Imperial College of Medicine- Ortho-Clinical Diagnostics- Pall- ProMetic Life Sciences- Proteome Sciences/Idexx- Q-One Biotech- Serono- U.S. Agricultural Research Servicec. Vaccines19. Cryptosporidium Parvuma. Backgroundb. Diagnostic Tests0 Histologic0 Laboratory Parasitology0 Serodiagnosisc. Vaccines and Drugs20. Cyclospora Cayetanensisa. Background0 Asymptomatic Infection0 Diarrhea in Immunocompetent Persons0 Diarrhea in Immunocompromisedersonsb. Diagnostic Testsc. Vaccines and Drugs21. Cytomegalovirusa. Background0 Chorioretinitis0 Gastrointestinal0 Central Nervous System Diseaseb. Diagnostic Testsc. Vaccines and Drugs22. Ebola Virusa. Background0 Epidemiology0 Hemorrhagic Feverb. Diagnostic Testsc. Vaccines and Drugs23. E. Colia. Background

0 Role of Escherichia Coli in

Causing Diarrhea

0 EPEC

0 ETEC

0 EIEC

0 EHEC

b. Diagnostic Tests

c. Vaccines and Drugs

24. EchoVirus

a. Background

0 Acute Aseptic Miningitisis

0 Encephalitis

0 Exanthems

0 Respiratory Disease

0 Myope;ricarditis

0 Neonatal Infections

b. Diagnostic Tests

c. Vaccines and Drugs

25. Encephalitis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

26. Enteroviruses

a. Background

b. Diagnostic Tests

0 Viral Isolation and Identification

0 Antibody Tests

c. Vaccines and Drugs

27. Epstein-Barr Virus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

28. Giardia Lamblia

a. Background

0 Life Cycle and Morphology

0 Morphology of Trophozoites

0 Clinical Disease

b. Diagnostic Tests

c. Vaccines and Drugs

29. Gonorrheaa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs30. Granuloma Inguinalea. Backgroundb. Diagnostic Testsc. Vaccines and Drugs31. Hantavirusa. Background0 Identification of the Agent0 Transmission0 Other Rodent Hantaviruses0 Distribution0 Hantavirus Diseases0 Epidemiology0 Addendum in Proof-Northeastern Connection0 Previously Unknown Pathogens0 Cases Nationwideb. Diagnostic Tests0 An Immunohistochemistry Approach0 Hantavirus Rapid Diagnostic Test0 ELISA Diagnosis of Hantavirus PulmonarySyndrome0 IgG ELISA0 IgM Capture ELISAc. Vaccines and Drugs32. Helicobacter Pyloria. Background0 Pathogenesis0 Role in Peptic Ulcer Disease0 Role in Gastric Cancer0 Nonulcer Dyspepsiab. Diagnostic Testsc. Vaccines and Drugs0 Specific Therapeutic Regimens0 Who Should Be Treated?0 Participants in Controlled Clinical Trials

0 Patients with Refractory Peptic Ulcer

0 Patients with Refractory NUD

0 Patients in High-Risk Groups for Gastric

Cancer

33. Hepatitis

a. Background

b. Hepatitis A

c. Hepatitis B

d. Hepatitis C

0 Classification

0 Transmission of Infection

0 Occupational Hazards

0 Acute Hepatitis

0 Diagnosis of Acute Infection

0 Chronic Hepatitis

0 HCV and Other Chronic Liver Diseases

0 Alcoholic Liver Disease

0 Hepatitis B Coinfection

0 Cirrhosis and Hepatocellular Carcinoma

0 Diagnostic Tests

0 Possible Indications for HCV RNA Testing

0 Conclusions and Future Direction

e. Hepatitis D

0 Historical Perspective

0 Epidemiology

0 HBV-HDV "Coinfection" vs. "Superinfection"

0 Methods of Detecting HDV

0 Prevention

f. Hepatitis E

0 Background

0 Prevalence of the Disease

0 Diagnostic Tests

0 Epidemiologic Serosurveys

0 Serologic Cross-Reactivity

g. Hepatitis G

0 Vaccines and Drugs

34. Herpes Simplex Virus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

35. Human Herpes Virus-6 (HHV-6)a. Background0 HIV-6 Infectionsb. Diagnostic Testsc. Vaccines and Drugs36. Influenza Virusesa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs37. Legionellaa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs38. Lyme Diseasea. Background0 Clinical Description0 Clinical Case Definition0 Laboratory Criteria for Diagnosis0 Case Classificationb. Diagnostic Testsc. Vaccines and Drugs39. Lymphogranuloma Venereum (LGV)a. Backgroundb. Diagnostic Testsc. Vaccines and Drugs40. Malariaa. Backgroundb. Diagnostic Tests0 Potential Diagnositic Problems with PositivePatients from Non-endemic Areas- Patient- Laboratory- Physicianc. Vaccines and Drugs41. Measles (Rubeola)a. Backgroundb. Diagnostic Testsc. Vaccines and Drugs

42. Meningitis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

0 Development of Polysaccharide Vaccines

0 Quadrivalent Vaccine Development

0 Meningococcal A.C.Y. & W-135 Vaccines

0 Efficacy of Group C Vaccine

0 Efficacy of Group A Vaccine

0 Combinations of Group A and C Vaccines

0 Group B Efficacy Trials

0 Future Direction

43. Microsporidium

a. Background

0 Prevalence and Geographic Distribution

0 Sources of Human Infection and Transmission

b. Diagnostic Tests

0 Light Microscopic Examination of Stool

Specimens By Chromotrope Staining

0 Stool Concentration Methods

0 Chemofluorescent Agents

0 Giemsa Staining of Stool Specimens

0 Cytologic Diagnosis

0 Histologic Examination

0 Electron Microscopy

0 Examination of Bodily Fluids

0 Examination of Tissue Sections

0 Immunofluorescence Detection Procedures

0 Serology

0 Cell Culture

0 Approach to Diagnosis

0 Evaluation of Patients with Presumptive

Intestinal Microsporidiosis

0 Evaluation of Patients with Presumptive

Ocular Microsporidiosis

c. Vaccines and Drugs

44. Mononucleosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

45. Mumpsa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs0 Efficacy of Vaccination0 Future Issues46. Mycoplasmaa. Background0 Ureaplasma Urealyticum & Mycoplasma Hominisb. Diagnostic Testsc. Vaccines and Drugs47. Papillomavirusesa. Background0 HPV in Cancer0 Cervical Neoplasmb. Diagnostic Testsc. Vaccines and Drugs0 Prevention48. Parvovirus B19a. Backgroundb. Diagnostic Testsc. Vaccines and Drugs49. Pneumoniaa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs50. Polyomavirusesa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs51. Pseudomonas Aeruginosaa. Background0 Virulence Factorsb. Diagnostic Testsc. Vaccines and Drugs52. Rabiesa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs

53. Respiratory Syncytial Virus (RSV)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

54. RhinoViruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

55. RotaVirus (REOVIRUS)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

56. Rubella(MEASLES)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

0 Developing Countries

0 Elimination and Eradication of Measles

0 New Developments

57. Salmonellosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

58. Septicemia

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

59. Shigellosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

60. Staphylococcus Aureus

a. Background

0 The Genus Taphylococcus

b. Diagnostic Tests

c. Vaccines and Drugs

0 Prevention

61. Streptococci

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs0 Group A Streptococci0 Group B Streptococci62. Syphilisa. Backgroundb. Diagnostic Tests0 Biopsy0 Rabbit Infectivity Testing0 Other Diagnostic Modalitiesc. Vaccines and Drugs0 Syphilis and HIV Infection0 Syphilis As a Cofactor for HIV Transmission0 Basic Science Issues63. Toxoplasmosisa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs64. Trichomonas Vaginalisa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs65. Tuberculosisa. Backgroundb. Diagnostic Tests0 Microscopic Characteristics0 Cultural Characteristics0 Detection of Antibodies0 Skin Tests0 MDRTBc. Vaccines and Drugs66. Vibrioa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs67. West Nile Virusa. Background- Clinical Syndromesb. Diagnostic Testsc. Vaccines and Drugs

68. Yersina

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

B. Instrumentation Review and Market Needs

0 Abbott AxSYM

0 Abbott IMx/IMx Select

0 Anagen AN2000/AuraFlex

0 Beckman Coulter Access

0 BioChem Pharma/SR1

0 BioMerieux/Vitek Vidas

0 Biotrol System 7000

0 Chiron ACS: Centaur

0 Chiron ACS: 180

0 J&J Diagnostics/Amersham Amerlite

0 J&J Diagnostics Vitros ECi

0 Olympus PK310

0 Roche Cobas Core

0 Roche Elecsys 1010/2010

0 Roche ES 22

0 Roche ES 33

0 Roche ES 300/300AL

0 Siemens ELISA Processor II/III

0 Siemens Immuno 1

0 Siemens/Opus/Plus/Magnum

0 Siemens Stratus

0 Tosoh AIA-1200/1200DX/NexIA/600

0 Wallac/Pharmacia Delfia

C. Emerging Diagnostic Technologies

1. DNA Probes

a. Technology Overview

b. Amplification Methods

0 Polymerase Chain Reaction

- Robotics

- Temperature Cyclers

- PCR Variations

0 Immuno-PCR

0 QC-PCR

0 DAP-PCR

0 Ligase Chain Reaction0 Branched DNA0 Q-Beta Replicase0 Nucleic-Acid Sequence-Based0 Strand Displacement Activation0 Self-Sustained Sequence Replicase2. Monoclonal Antibodies3. Immunoassaysa. Technological Principleb. Enzyme Immunoassays (EIA)0 Overview0 ELISA0 Dot Immunobinding Assays0 Capillary Immunoassays0 Particle-Membrane CaptureImmunoassays0 Enzyme Amplificationc. Fluorescent Immunoassays0 Fluorescence Polarization0 Time-Resolved Pulse Fluorescenced. Luminescence0 Chemiluminescence0 Bioluminescencee. Latex Agglutinationf. Immunoprecipitation4. Differential Light Scattering5. Microcomputers and Automation6. Artificial Intelligence7. Liposomes8. Flow Cytometry9. Chromatography10. MRI11. Gel Microdroplets12. OtherD. Personal TestingE. Worldwide Business EnvironmentF. Worldwide Market StructureG. Worldwide Market Size and Growth

U.K.

A. Executive Summary

B. Business Environment

C. Market Structure

D. Market Size, Growth and Major Suppliers

Major Product Development Opportunities

A. Instrumentation

B. Reagent Kits and Test Systems/Panels

C. Computers, Software and Automation

D. Auxiliary Products

Design Criteria for Decentralized Testing Products

Alternative Market Penetration Strategies

A. Internal Development

B. Collaborative Arrangements

C. University Contracts

D. Distribution Strategies for Decentralized

Testing Markets

1. Marketing Approaches

2. Product Complexity

3. Customer Preference

4. Established Suppliers

5. Emerging Suppliers

6. Major Types of Distributors

7. Market Segmentation

Potential Market Entry Barriers and Risks

A. Market Maturity

B. Cost Containment

C. Competition

D. Technological Edge and Limitations

E. Patent Protection

F. Regulatory Constraints

G. Decentralized Testing Market Challenges

Competitive Assessments- Abbott- Affymetrix- Beckman Coulter- Becton Dickinson- bioMerieux- Bio-Rad- Cepheid- Diamedix- DiaSorin- Eiken Chemical- Enzo Biochem- Fujirebio- Gen-Probe- Hologic- ID Biomedical- J&J Diagnostics- Kreatech- Life Technology- Lonza- Nanogen- Novartis Diagnostics- Qiagen- Roche- Scienion- Sequenom- SeraCare- Siemens- Takara Bio- Thermo Fisher- Wallac- Wako

List of Tables

Major Companies Developing or Marketing AIDS Tests

Major Companies Developing or Marketing Adenovirus

Tests

Major Companies Developing or Marketing Bartonella

Tests

Major Companies Developing or Marketing

Campylobacter Tests

Major Companies Developing or Marketing Candida

Tests

Major Companies Developing or Marketing Chlamydia

Tests

Major Companies Developing or Marketing Clostridium

Tests

Major Companies Developing or Marketing Coronavirus

Tests

Major Companies Developing or Marketing Cryptosporidium

Tests

Major Companies Developing or Marketing CMV Tests

Major Companies Developing or Marketing Echovirus

Tests

Major Companies Developing or Marketing Enterovirus

Tests

Major Companies Developing or Marketing EBV Tests

Major Companies Developing or Marketing GiardiaTestsMajor Companies Developing or Marketing GonorrheaTestsMajor Companies Developing or Marketing HantavirusTestsMajor Companies Developing or Marketing HelicobacterPylori TestsMajor Companies Developing or Marketing HepatitisTestsMajor Companies Developing or Marketing HerpesTestsMajor Companies Developing or Marketing InfluenzaTestsMajor Companies Developing or Marketing LegionellaTestsMajor Companies Developing or Marketing Lyme DiseaseTestsMajor Companies Developing or Marketing LymphogranulomaTestsMajor Companies Developing or Marketing MalariaTestsMajor Companies Developing or Marketing MeaslesTestsMajor Companies Developing or Marketing MeningitisTests

Major Companies Developing or Marketing Microsporidium

Tests

Major Companies Developing or Marketing

Mononucleosis Tests

Major Companies Developing or Marketing Mumps Tests

Major Companies Developing or Marketing Mycoplasma

Tests

Major Companies Developing or Marketing Papilloma

Virus Tests

Major Companies Developing or Marketing Parvovirus

Tests

Major Companies Developing or Marketing Pneumonia

Tests

Major Companies Developing or Marketing RSV Tests

Major Companies Developing or Marketing Rotavirus

Tests

Major Companies Developing or Marketing Rubella

Tests

Major Companies Developing or Marketing Salmonella

Tests

Major Companies Developing or Marketing Septicemia

Tests

Major Companies Developing or Marketing Shigella

Tests

Major Companies Developing or Marketing Staphylococci

Tests

Major Companies Developing or MarketingStreptococci TestsMajor Companies Developing or Marketing SyphilisTestsMajor Companies Developing or Marketing ToxoplasmosisTestsMajor Companies Developing or Marketing TrichomonasTestsMajor Companies Developing or Marketing TuberculosisTestsMajor Companies Developing or Marketing West NileTestsMajor Companies Developing or Marketing Yersinia TestsWorldwide All Market Segments LaboratoriesPerforming Microbiology Tests by CountryWorldwide All Market Segments Total Microbiology TestVolume Forecast by CountryWorldwide All Market Segments Total MicrobiologyDiagnostics Market Forecast by CountryInfectious Disease Tests Major Issues and MarketPotential For Personal TestingU.K. Summary TableAll Infectious Diseases Test Volume and DiagnosticsSales Forecast by Market SegmentU.K.Laboratories Performing Infectious Disease Testsby Market Segment

U.K.

Hospital Laboratories Performing Infectious Disease

Tests by Bed Size

U.K.

Commercial/Private Laboratories Performing Infectious

Disease Tests by Annual Test Volume

U.K.

All Market Segments Infectious Disease Test Volume Forecast

U.K.

Hospital Laboratories Infectious Disease Test Volume Forecast

U.K.

Blood Banks Infectious Disease Test Volume Forecast

U.K.

Public Health Laboratories Infectious Disease Test

Volume Forecast

U.K.

Commercial/Private Laboratories Infectious Disease

Test Volume Forecast

U.K.

All Market Segments Infectious Disease Diagnostics

Market Forecast

U.K.

Hospital Laboratories Infectious Disease Diagnostics

Market Forecast

U.K.

Blood Banks Infectious Disease Diagnostics Market Forecast

U.K.

Public Health Laboratories Infectious Disease

Diagnostics Market Forecast

U.K.Commercial/Private Laboratories Infectious DiseaseDiagnostics Market ForecastU.K.HIV or HIVI/HIVII Test Volume and Diagnostics SalesForecast by Market SegmentU.K.HTLV I or HTLV I/HTLV II Test Volume and DiagnosticsSales Forecast by Market SegmentU.K.HIVAg Test Volume and Diagnostics Sales Forecast by MarketSegmentU.K.Western Blot/Other Confirmatory Test Volume andDiagnostics Sales Forecast by Market SegmentU.K.AdenovirusTest Volume and Diagnostics Sales Forecast by Market SegmentU.K.AeromonadsTest Volume and Diagnostics Sales Forecast by Market SegmentU.K.BEATest Volume and Diagnostics Sales Forecast by Market Segment

U.K.

Blastocystis Hominis Test Volume and Diagnostics Sales

Forecast by Market Segment

U.K.

Campylobacter

Test Volume and Diagnostics Sales Forecast by Market Segment

U.K.

Candida

Test Volume and Diagnostics Sales Forecast by Market Segment

U.K.

Chancroid

Test Volume and Diagnostics Sales Forecast by Market Segment

U.K.

Chlamydia Test Volume and Diagnostics Sales Forecast by Market

Segment

U.K.

Clostridium Test Volume and Diagnostics Sales Forecast by

Market Segment

U.K.

Coronavirus Test Volume and Diagnostics Sales Forecast by

Market Segment

U.K.

CoxsackieVirus Test Volume and Diagnostics Sales Forecast by

Market Segment

U.K.

Cryptosporidium Test Volume and Diagnostics Sales Forecast by

Market Segment

U.K.

Cyclospora Test Volume and Diagnostics Sales Forecast by

Market Segment

U.K.CMV Test Volume and Diagnostics Sales Forecast by MarketSegmentU.K.E. Coli Test Volume and Diagnostics Sales Forecast by MarketSegmentU.K.Echovirus Test Volume and Diagnostics Sales Forecast by MarketSegmentU.K.Encephalitis Test Volume and Diagnostics Sales Forecast byMarket SegmentU.K.Enterovirus Test Volume and Diagnostics Sales Forecast byMarketSegmentU.K.EBV Test Volume and Diagnostics Sales Forecast by MarketSegmentU.K.Giardia Test Volume and Diagnostics Sales Forecast by MarketSegmentU.K.Gonorrhea Test Volume and Diagnostics Sales Forecast by MarketSegmentU.K.Granuloma Inguinale Test Volume and Diagnostics SalesForecast by Market SegmentU.K.Helicobacter Pylori Test Volume and Diagnostics SalesForecast by Market Segment

U.K.

HAV NAT Test Volume and Diagnostics Sales Forecast by Market

Segment

U.K.

HBV NAT Test Volume and Diagnostics Sales Forecast by Market

Segment

U.K.

HbsAg Test Volume and Diagnostics Sales Forecast by Market

Segment

U.K.

Hepatitis C Test Volume and Diagnostics Sales Forecast by

Market Segment

U.K.

Anti-HBc Test Volume and Diagnostics Sales Forecast by Market

Segment

U.K.

Anti-HBs Test Volume and Diagnostics Sales Forecast by Market

Segment

U.K.

Anti-HAV Test Volume and Diagnostics Sales Forecast by Market

Segment

U.K.

Hepatitis Delta Test Volume and Diagnostics Sales

Forecast by Market Segment

U.K.

HBcAg Test Volume and Diagnostics Sales Forecast by Market

Segment

U.K.HBeAg Test Volume and Diagnostics Sales Forecast by MarketSegmentU.K.Herpes Simplex I and II Test Volume and DiagnosticsSales Forecast by Market SegmentU.K.Herpes Type VI Test Volume and DiagnosticsSales Forecast by Market SegmentU.K.HTLV-I/II Test Volume and DiagnosticsSales Forecast by Market SegmentU.K.Influenza Test Volume and Diagnostics Sales Forecast by MarketSegmentU.K.Legionella Test Volume and Diagnostics Sales Forecast byMarket SegmentU.K.Lyme Disease Test Volume and Diagnostics Sales Forecast byMarket SegmentU.K.Lymphogranuloma Test Volume and Diagnostics Sales Forecast byMarket SegmentU.K.Malaria Test Volume and Diagnostics Sales Forecast by MarketSegmentU.K.Measles Test Volume and Diagnostics Sales Forecast by MarketSegment

U.K.

Meningitis Test Volume and Diagnostics Sales Forecast by

Market Segment

U.K.

Microsporidium Test Volume and Diagnostics Sales Forecast by

Market Segment

U.K.

Mononucleosis Test Volume and Diagnostics Sales Forecast by

Market Segment

U.K.

Mumps Test Volume and Diagnostics Sales Forecast by Market

Segment

U.K.

Mycoplasma Test Volume and Diagnostics Sales Forecast by

Market Segment

U.K.

Papilloma Virus Test Volume and Diagnostics Sales Forecast by

Market Segment

U.K.

Parvovirus Test Volume and Diagnostics Sales Forecast by

Market Segment

U.K.

Pneumonia Test Volume and Diagnostics Sales Forecast by

Market Segment

U.K.

Polyomaviruses Test Volume and Diagnostics Sales

Forecast by Market Segment

U.K.

Pseudomonas Test Volume and Diagnostics Sales Forecast by

Market Segment

U.K.Rabies Test Volume and Diagnostics Sales Forecast byMarket SegmentU.K.RSV Test Volume and Diagnostics Sales Forecast by MarketSegmentU.K.Rhinovirus Test Volume and Diagnostics Sales Forecast byMarket SegmentU.K.Rotavirus Test Volume and Diagnostics Sales Forecast byMarket SegmentU.K.Rubella Test Volume and Diagnostics Sales Forecast by MarketSegmentU.K.Salmonella Test Volume and Diagnostics Sales Forecast byMarket SegmentU.K.Septicemia Test Volume and Diagnostics Sales Forecast byMarket SegmentU.K.Shigella Test Volume and Diagnostics Sales Forecast byMarket SegmentU.K.Staphylococci Test Volume and Diagnostics Sales Forecast byMarket SegmentU.K.Streptococci Test Volume and Diagnostics Sales Forecast byMarket Segment

U.K.

Syphilis Test Volume and Diagnostics Sales Forecast by

Market Segment

U.K.

Toxoplasmosis Test Volume and Diagnostics Sales Forecast by

Market Segment

U.K.

Trichomonas Test Volume and Diagnostics Sales Forecast by

Market Segment

U.K.

Tuberculosis Test Volume and Diagnostics Sales Forecast by

Market Segment

U.K.

Vibrio Test Volume and Diagnostics Sales Forecast

by Market Segment

U.K.

West Nile Test Volume and Diagnostics Sales Forecast

by Market Segment

U.K.

Yersinia Test Volume and Diagnostics Sales Forecast

by Market Segment

U.K.

AIDS Testing Market Diagnostics Sales by Major

Supplier

U.K.

Campylobacter Testing Market Diagnostics Sales by

Major Supplier

U.K.Candida Testing Market Diagnostics Sales by MajorSupplierU.K.Gonorrhea Testing Market Diagnostics Sales byMajor SupplierU.K.Hepatitis Testing Market Diagnostics Sales by MajorSupplierU.K.Hepatitis C Testing Market Diagnostics Sales byMajor SupplierU.K.Influenza Testing Market Diagnostics Sales byMajor SupplierU.K.Mycoplasma Testing Market Diagnostics Sales byMajor SupplierU.K.Pneumonia Testing Market Diagnostics Sales by MajorSupplierU.K.RSV Testing Market Diagnostics Sales by Major SupplierU.K.Rubella Testing Market Diagnostics Sales by MajorSupplierU.K.Septicemia Testing Market Diagnostics Sales by MajorSupplier

U.K.

Shigella Testing Market Diagnostics Sales by Major

Supplier

U.K.

Streptococci Testing Market Diagnostics Sales by

Major Supplier

U.K.

Syphilis Testing Market Diagnostics Sales by Major

Supplier

U.K.

Tuberculosis Testing Market Diagnostics Sales by

Major Supplier

U.K.

Infectious Disease Diagnostic Testing Instrumentation

Major Systems Estimated Placements and Installed Base

To order this report:In Vitro Diagnostic Industry: Future UK Microbiology Testing Market Outlook

More  

Market Research Report

Check our  

Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

Visit link:
Future UK Microbiology Testing Market Outlook

Deutsche agrees record longevity swap deal

Deutsche agrees record longevity swap deal

The swap, announced during Aegon's results this morning, is significant for two reasons - its size, and the fact that Deutsche says it has managed to pass its resulting exposure to longer Dutch life expectancy on to third parties - anonymous financial investors in the capital markets.

These might include other banks, hedge funds, or specialist insurance-linked securities funds, all willing to bet that Aegon's provisions for rising Dutch life expectancy are, in fact, too high. Deutsche is understood to have "packaged" its exposure from the Aegon deal into various kinds of investment products for these institutions to buy.

Usually, when banks and insurers sign longevity deals, they subsequently pass the risk onto reinsurers - firms that specialise in covering insurers. But capacity in this market is limited.

The €12bn swap also contains an irony for Aegon, since the Dutch group had once set out its own plans for entering the related "pensions buyout" market in the UK. Aegon launched a joint venture with Swiss bank UBS in late 2008 to do this, but rethought the plans in June 2010, following a restructuring of its UK life business.

Deutsche, meanwhile, arrived in pensions swaps with a bang in January 2010, signing a £3bn longevity deal with BMW on behalf of its £5bn UK pension fund. It owns a UK insurance subsidiary, Abbey Life, through which these transactions tend to be structured.

Its deal with Aegon today is also one of first large, public longevity swaps to take place outside the UK. Most of those to date have involved UK pension schemes, such as those for BMW, Rolls-Royce and ITV.

In a statement, Clare Hennings, head of structured insurance solutions at Deutsche, said: “We believe this market will continue to grow as insurance companies and pension funds look at new ways to manage their liabilities, while investors seek diversified investment opportunities."

Aegon said this morning that the swap "reduces required capital at an attractive cost of capital", and these deals can be positive for companies' share prices. Figures from City law firm Freshfields, released late last month, suggested companies who reduce financial risks in their pension schemes enjoy an average 2.1% boost to their shares.

Yesterday, the UK defence group BAE Systems reported a £1.5bn write-off related to the deficit in its pension funds, equalling its 2011 pre-tax profits. The loss is a paper one, but gives an indication of what could be a bruising valuation of its £9bn main scheme that is currently underway. If a big deficit is revealed BAE's cash payments could be in line for an increase.

BAE's shares were down 7.8p to 325.2p yesterday, though the market was also disappointed by the firm's poor trading prospects.

Aegon's deal does not affect its pension scheme, but the life-expectancy risk in its annuity book is similar. Its shares were up 0.2% to €3.95 this morning, as of 11.21am GMT.

• Separately, Aegon also said its UK chief executive, who leads the substantial UK operations that the Dutch group inherited from its acquisition of Scottish Equitable in 1994, would be joining its group management board.

Adrian Grace's promotion is a "a reflection of the continued importance our business in the UK represents within our strategic priorities" according to group chief executive Alex Wynaendts.

The rest is here:
Deutsche agrees record longevity swap deal

Aegon clinches record longevity protection deal

LONDON, Feb 17 (Reuters) - Dutch life insurer Aegon (LSE: AGN.L - news) has struck a 12 billion euro ($15.65 billion) deal with Deutsche Bank (Xetra: 514000 - news) to protect itself against the financial impact of customers living longer than expected, the biggest such transaction in Europe (Chicago Options: ^REURUSD - news) .

Under the deal, Deutsche Bank is taking a fee to cover the cost of unforeseen increases in the lifespan of Aegon customers accounting for 12 billion euros of reserves, about one third of the insurer's Dutch business, the two companies said on Friday.

Deutsche Bank has in turn passed on most of the risk to capital market investors through private bond and swap placements.

Such deals are tipped for strong growth as unexpected increases in pensioner lifespans, fuelled by medical advances and lifestyle changes, inflict potentially crippling extra costs on insurers and pension funds.

"We believe this market will continue to grow as insurance companies and pension funds look at new ways to manage their liabilities while investors seek diversified investment opportunities," said Clare Hennings, Deutsche Bank's head of structured insurance solutions.

In November, Deutsche Bank provided protection from longevity increases on 3 billion pounds ($4.72 billion) of liabilities in British aero engine maker Rolls Royce (LSE: RR.L - news) 's pension fund.

British life insurer Legal & General (LSE: LGEN.L - news) and reinsurer Hannover Re last month agreed a 1 billion pound longevity transfer deal for British glass maker Pilkington's staff pension scheme.

Britain's pension risk transfer market, where companies pay insurers or banks to shoulder some of the investment risk associated with their retirement schemes, reached a record 9 billion pounds last year, according to pension consultants Hyman Robertson.

Separately on Friday, Aegon said it missed fourth-quarter profit estimates after taking several one-off charges and expected the euro zone crisis to continue to affect the economy and financial markets. ($1 = 0.7668 euros) ($1 = 0.6350 British pounds) (Reporting by Myles Neligan; Editing by Jon Loades-Carter)

View original post here:
Aegon clinches record longevity protection deal

PRU Expands Longevity Risk Biz – Analyst Blog

Prudential Retirement, a unit of Prudential Financial Inc. ( PRU ) has extended its partnership with U.K.-based Rothesay Life, a wholly-owned subsidiary of The Goldman Sachs Group Inc. ( GS ), as a reinsurance partner for its pension-related longevity risk. The agreement is the first reinsurance transaction for Prudential in 2012.

The transaction is intended to cover pension liability values worth approximately $665 million. The reinsurance contracts secure the retirement benefits of Uniq Plc Pension Scheme members, those who have been insured by Rothsay Life. These contracts will be issued by Prudential Retirement Insurance and Annuity Company, Hartford, CT.

Prudential started providing coverage on longevity risk last year and had provided coverage of approximately $723 million to Rothesay Life and Paternoster. This was the largest longevity transaction announced so far by the company. The company was also chosen by Deutsche Bank ( DB ) as a reinsurance partner to transfer $780 million of longevity risk of Deutsche Bank Rolls-Royce Pension Fund.

Longevity risk is faced by pension or annuity providers. It is an indication that customers may live longer than expected. In such a scenario, providers would be exposed to higher-than-expected payout ratios.

Longevity worries continue to bother pension funds and insurers as medical advancements and healthier lifestyles have led to an increase in the average lifespan. A report by a major reinsurer, Swiss Re, stated that underestimating life expectancy by just one year can increase pension liability burden by approximately 5%.

This trend has made insurance risk transfer very important as longevity de-risking would release the capital locked up in such businesses, thus restoring capital flexibility for businesses, especially in the current tight economic scenario.

Consequently, providers are keen on finding new ways of managing their liabilities or transferring risk. Of late, a growing demand for longevity risk transfer has led to the emergence of other innovative reinsurance agreements like Longevity Swap transactions and Cross-Border risk transfer.

Other factors such as a declining interest rate, greater accounting and regulatory changes and larger-than-expected funding contributions have also increased the risk appetite of pension plan sponsors. There has been a worldwide increase in pension de-risking demand with U.K. emerging as the leading market. The country has approximately $1 trillion in defined-benefit pension scheme liability.

Moreover, Solvency II is also pressurizing European insurers to maintain greater capital levels. Prudential foresees a growing opportunity in this area.

On the other end of the spectrum, Prudential, which runs a significant mortality risk due to its niche presence in the life insurance market, is planning to counter the losses or gains from this risk with gains and losses from longevity risk.

If longevity systemically improves, there would be fewer mortality claims. This would eventually improve profitability and help offset losses in the longevity business. Conversely, if the mortality portfolio shows an increase in the number of deaths, there should be an offsetting profit from longevity risk.

 
DEUTSCHE BK AG ( DB ): Free Stock Analysis Report
 
GOLDMAN SACHS ( GS ): Free Stock Analysis Report
 
PRUDENTIAL FINL ( PRU ): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Read more here:
PRU Expands Longevity Risk Biz - Analyst Blog

PRU Expands Longevity Risk Biz

Prudential Retirement, a unit of Prudential Financial Inc. (NYSE:PRU - News) has extended its partnership with U.K.-based Rothesay Life, a wholly-owned subsidiary of The Goldman Sachs Group Inc. (NYSE:GS - News), as a reinsurance partner for its pension-related longevity risk. The agreement is the first reinsurance transaction for Prudential in 2012.

The transaction is intended to cover pension liability values worth approximately $665 million. The reinsurance contracts secure the retirement benefits of Uniq Plc Pension Scheme members, those who have been insured by Rothsay Life. These contracts will be issued by Prudential Retirement Insurance and Annuity Company, Hartford, CT.

Prudential started providing coverage on longevity risk last year and had provided coverage of approximately $723 million to Rothesay Life and Paternoster. This was the largest longevity transaction announced so far by the company. The company was also chosen by Deutsche Bank (NYSE:DB - News) as a reinsurance partner to transfer $780 million of longevity risk of Deutsche Bank Rolls-Royce Pension Fund.

Longevity risk is faced by pension or annuity providers. It is an indication that customers may live longer than expected. In such a scenario, providers would be exposed to higher-than-expected payout ratios.

Longevity worries continue to bother pension funds and insurers as medical advancements and healthier lifestyles have led to an increase in the average lifespan. A report by a major reinsurer, Swiss Re, stated that underestimating life expectancy by just one year can increase pension liability burden by approximately 5%.

This trend has made insurance risk transfer very important as longevity de-risking would release the capital locked up in such businesses, thus restoring capital flexibility for businesses, especially in the current tight economic scenario.

Consequently, providers are keen on finding new ways of managing their liabilities or transferring risk. Of late, a growing demand for longevity risk transfer has led to the emergence of other innovative reinsurance agreements like Longevity Swap transactions and Cross-Border risk transfer.

Other factors such as a declining interest rate, greater accounting and regulatory changes and larger-than-expected funding contributions have also increased the risk appetite of pension plan sponsors. There has been a worldwide increase in pension de-risking demand with U.K. emerging as the leading market. The country has approximately $1 trillion in defined-benefit pension scheme liability.

Moreover, Solvency II is also pressurizing European insurers to maintain greater capital levels. Prudential foresees a growing opportunity in this area.

On the other end of the spectrum, Prudential, which runs a significant mortality risk due to its niche presence in the life insurance market, is planning to counter the losses or gains from this risk with gains and losses from longevity risk.

If longevity systemically improves, there would be fewer mortality claims. This would eventually improve profitability and help offset losses in the longevity business. Conversely, if the mortality portfolio shows an increase in the number of deaths, there should be an offsetting profit from longevity risk.

Read the Full Research Report on PRU

Read the Full Research Report on DB

Read the Full Research Report on GS

Zacks Investment Research

More From Zacks.com

Read more from the original source:
PRU Expands Longevity Risk Biz

Health games emerge as important new therapeutic tools for physical and mental health and well-being

Public release date: 16-Feb-2012
[ | E-mail | Share ]

Contact: Cathia Falvey
cfalvey@liebertpub.com
914-740-2100 x2165
Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY -- Millions of dollars and immeasurable hours of research and development are being invested to develop and employ increasingly sophisticated hardware and software technologies to deliver innovative new personalized health care interventions. Digital games are rapidly becoming an important tool for improving lifestyle habits, behavior modification, self-management of illness and chronic conditions, and motivating and supporting physical activity, according to a provocative Expert Panel Discussion in the premier issue of Games for Health Journal, a new bimonthly peer-reviewed publication from Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com). The premier issue is available free online at http://www.liebertpub.com/g4h.

The Journal will be the only source for a broad range of hard-to-find and timely information related to health games. For example, the first issue offers a unique Roundtable Discussion, "Health Games Come of Age," an insightful conversation with leaders in the games for health field. Tom Baranowski, PhD, Baylor College of Medicine; Peter Bingham, MD, University of Vermont; Debra Lieberman, PhD, University of California, Santa Barbara; Ernie Medina, DrPH, Medplay Technologies; Jesse Schell, MS, Carnegie Mellon University; and Sam K. Yohannon, PT, MS, Cornell University Medical Center share their unique approaches and the creative evidenced-based outcomes research that has brought health games to the forefront of innovative patient care.

The Journal breaks new ground as the first to address this emerging and increasingly important area of health care and will provide a bimonthly forum in print and online for academic and clinical researchers, game designers and developers, health care providers, insurers, and information technology leaders. Articles in the Journal explore the use of game technology in a wide variety of clinical applications in disease prevention, promotion, and monitoring, including nutrition, weight management, medication adherence, diabetes monitoring, post-traumatic stress disorder, Alzheimer's, and cognitive, mental, emotional, and behavioral health.

The Journal is under the leadership of Bill Ferguson, PhD and a distinguished editorial board (http://www.liebertpub.com/editorialboard/games-for-health-journal/588/) including leaders from academia, health care, information technology, and government.

Other key contributions in this issue include an original article on "Use of Nintendo? Wii? During Physical Therapy of an Adult with Lower Extremity Burns" describing a fascinating intervention using health games to accelerate returning severe burn victims to independent living. "The United Health Group's Rx for Longer, Healthier Lives" is an informative program profile that examines the huge health provider's commitment to encouraging and enabling healthier lifestyles through games. Their goal is greater availability and lower cost of health care for people who actively manage their own health and well-being

A clinical brief on "Evaluating Efficacy and Validating Games for Health" suggests the importance and process for objectively assessing the results of games used to improve patients' health. A fascinating interview with Ben Sawyer, Co-Founder of Digitalmill?"Games? Seriously!"--explores the driving forces in the field and the gamification of health.

"The growing breadth and depth of research in health games will have powerful impacts on all stages of life, from infants with autism to geriatric patients wanting to extend their active lives," says Editor-in-Chief Bill Ferguson. "These advancements will impact the nature and availability of preventive and remedial care from physicians to therapists to self-management. The Journal will be a powerful voice for the researchers and clinicians, as well as a resource for state-of-the-art developments for everyone concerned with human well-being."

###

Mary Ann Liebert, Inc. (http://www.liebertpub.com) is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Cyberpsychology, Behavior, and Social Networking and Telemedicine & e-Health. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available at http://www.liebertpub.com.

Mary Ann Liebert, Inc.
140 Huguenot Street, 3rd Floor
New Rochelle, NY 10801-5215, USA


[ | E-mail | Share ]

 

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Original post:
Health games emerge as important new therapeutic tools for physical and mental health and well-being

DNA Robots Deliver Deadly Punch to Bad Cells

New nano-robots made from DNA can transport a precise deadly cargo to unhealthy cells.

The tiny robots bring closer the long-held nanotech dream of a fleet of small robots that can storm the body and kill diseased cells one by one.

"People already know about using antibodies to kill cells," said Shawn Douglas, a technology fellow at Harvard Medical School's Wyss Institute, which develops bio-inspired medical materials and devices. "The selective targeting and exposing the payload, that's the big novel thing."

PHOTOS: Extraordinary Beauty of the NanoArt World

Douglas and genetics research fellow Ido Bachelet made the new DNA nano-robots at Harvard with genetics professor George M. Church, known for helping to launch the Human Genome Project. Their research will appear in a forthcoming issue of the journal Science.

First, Bachelet and Douglas wondered if they could combine their respective expertise in immunology and building nanostructures to design a robot that would mimic the body's immune system. It would recognize infected cells and push their self-destruct buttons.

Previous breakthroughs included a nanoscale cube with a lid debuted in 2009 that self-assembled in a process called "DNA origami." Adding DNA strands caused the box to open. But Douglas felt that making the box so it got delivered to the right cells would be too difficult. So would making the mechanisms to enter and reprogram the bad cells.

Then Bachelet suggested that they didn't have to reprogram anything. They just had to make a structure that could deliver the right antibodies to a cell's surface with a clear message: stop dividing.

"We could actually make an open-ended container and then all it would need to do is just turn itself inside out," Douglas said.

Their nano-robot is constructed from DNA in a clam shell shape held shut with a special DNA lock. That lock is designed to recognize certain kinds of cancer cells. When it encounters one, the robot springs open and exposes the antibody payload.

NEWS: How To Make Nano-Origami

So, in the fight against cancer, these nano-robots could be the equivalent of sending SEAL Team Six.

"Our ability to perform that 'surgical strike' with nanoscale devices will ultimately allow us to do so in a way that's safe for the patient," Douglas said.

"Once we had the idea in mind that we don’t actually need to build some cage that gets inside the cell, we can actually just talk to the surface, we realized that all the other steps solved themselves."

-- Shawn Douglas, Harvard technology fellow and bioinspired engineering postdoc on his A-Ha! Moment

In the lab, their nano-robot successfully blew up lymphoma and leukemia cells, leaving good cells alone. Doing one of these reactions typically requires 100 billion copies of the robot. In order to start testing their creation on animals, the Harvard postdocs will have to figure out how to scale up to trillions.

Although the nano-robot works in a Petri dish, it will have to be redesigned for a trip through the bloodstream, Douglas said. Modifications are necessary to prevent the particle from getting cleared out by the kidneys or the liver before it has a chance to perform.

"My dream is for one of these devices to ultimately go through clinical trials and become an actual therapeutic that would be a novel treatment for some type of cancer," Douglas said.

Kurt Gothelf is a professor of chemistry at Aarhus University in Denmark, and the director of the Danish National Research Foundation's Center for DNA Nanotechnology. He and his colleagues made the self-assembling nanoscale DNA box with a lid in 2009.

"This is one of the things the field has needed, something to show that, hey, this can actually be useful" Gothelf said of the Harvard group's DNA nano-robot. Although their smart nanodevice isn't curing cancer yet, it does mark an important step along the way, he added.

"People have been talking a lot about robots that enter your body, and go to a place where something is wrong and fix it," Gothelf said. "This is the first example that this might come true one day."

Here is the original post:
DNA Robots Deliver Deadly Punch to Bad Cells

Posted in DNA

'DNA robot' targets cancer cells

17 February 2012 Last updated at 07:42 ET By Jason Palmer Science and technology reporter, BBC News

Scientists have developed and tested a "DNA robot" that delivers payloads such as drug molecules to specific cells.

The container was made using a method called DNA origami, in which long DNA chains are folded in a prescribed way.

Then, so-called aptamers - which can recognise specific cell types - were used to lock the barrel-shaped robot.

In lab tests described in Science, the locks opened on contact with cancer cell proteins, releasing antibodies that halted the cells' growth.

The method could find wide use in biological applications, where this kind of "specificity" is highly prized.

Lead author of the research, Shawn Douglas of the Wyss Institute at Harvard University, said the result brings together several recent research strands.

"We've been working on figuring out how to build different shapes using DNA over the past several years, and other researchers have used antibodies as therapeutics, in order to manipulate cell signalling, and yet others have demonstrated that aptamers can be used to target cancer cell types," Dr Douglas told BBC News.

"The novel part is really integrating all those different pieces and putting them together in a single device that works."

In essence, the approach co-opts a number of strategies of our immune systems, with the robots playing the role of white blood cells that hunt down problematic cells and destroy them.

The team tested the robots using several cultures of cancer cells including lymphoma and leukemia, with corresponding payloads of antibodies.

Because DNA is found in nearly all of our cells, Dr Douglas said the robots posed fewer problems of toxicity than many materials would have.

Scientists have already discovered a large number of different aptamers that can "recognise" proteins corresponding to different diseases, so the approach could in principle be adapted to a wide range of applications.

Dr Douglas said that there was still much optimisation to be done on the robots; for now the team will create a great many of them to be tested in an animal model.

Continued here:
'DNA robot' targets cancer cells

Posted in DNA

DNA Robot Kills Cancer Cells

Nature | Health

Device identifies target then releases deadly payload.

By Alla Katsnelson of Nature magazine

DNA origami, a technique for making structures from DNA, may be more than just a cool design concept. It can also be used to build devices that can seek out and destroy living cells. [View a "DNA Origami" Slide Show.]

The nanorobots, as the researchers call them, use a similar system to cells in the immune system to engage with receptors on the outside of cells.

"We call it a nanorobot because it is capable of some robotic tasks," says Ido Bachelet, a postdoctoral fellow at Harvard Medical School in Boston, Massachusetts, and one of the authors of the study, which is published in the February 17 issue of Science. Once the device recognizes a cell, he explains, it automatically changes its shape and delivers its cargo.

The researchers designed the structure of the nanorobots using open-source software, called Cadnano, developed by one of the authors--Shawn Douglas, a biophysicist at Harvard's Wyss Institute for Biologically Inspired Engineering. They then built the bots using DNA origami. The barrel-shaped devices, each about 35 nanometers in diameter, contain 12 sites on the inside for attaching payload molecules and two positions on the outside for attaching aptamers, short nucleotide strands with special sequences for recognizing molecules on the target cell. The aptamers act as clasps: once both have found their target, they spring open the device to release the payload.

"You can think about it as a sort of combination lock," says Bachelet. "Only when both markers are in place, can the entire robot open."

The researchers tested six combinations of aptamer locks, each of which were designed to target different types of cancer cells in culture. Those designed to hit a leukemia cell could pick that cell out of a mixture of cell types then release their payload--in this case, an antibody--to stop the cells from growing. They also tested payloads that could activate the immune system.

The work "takes us one more step along the path from the smartest drugs of today to the kind of medical nanobots we might imagine," says Paul Rothemund, a computational bioengineer at the California Institute of Technology in Pasadena, and inventor of DNA origami.

Right on target

Because the nanorobots can be programmed to release their payload only when the target cell is in the correct disease state, they achieve a specificity that other drug-delivery methods lack, says Hao Yan, a chemist and nanotechnologist at Arizona State University in Tempe. "This really takes advantage of the programmability of DNA nanotechnology."

Whether or not these structures will work in a living organism remains to be seen. For one thing, they are designed to communicate with molecules on a cell's surface. "If your therapeutic target is inside the cell, it's going to be tricky," says Bachelet.

What's more, the nanorobots are quickly cleared by the liver or destroyed by nucleases, enzymes chew up stray bits of DNA. It might be possible to coat them with a substance such as polyethylene glycol, widely used to boost the length of time a drug can remain in the body, says Douglas, or "maybe to borrow inspiration from other biomolecules or cells"--such as red blood cells--"that can circulate in the blood for a long time". He and his colleagues are just beginning to think about testing the nanobots in mice, he says.

"If these sorts of problems can be solved, then the nanorobots have a chance at becoming real therapeutics," Rothemund says.

This article is reproduced with permission from the magazine Nature. The article was first published on February 16, 2012.

Go here to see the original:
DNA Robot Kills Cancer Cells

Posted in DNA

DNA robots hunt down and kill cancer cells

New nano-robots made from DNA can transport a precise deadly cargo to unhealthy cells.

The tiny robots bring closer the long-held nanotech dream of a fleet of small robots that can storm the body and kill diseased cells one by one.

"People already know about using antibodies to kill cells," said Shawn Douglas, a technology fellow at Harvard Medical School's Wyss Institute, which develops bio-inspired medical materials and devices. "The selective targeting and exposing the payload, that's the big novel thing."

PHOTOS: Extraordinary Beauty of the NanoArt World

Douglas and genetics research fellow Ido Bachelet made the new DNA nano-robots at Harvard with genetics professor George M. Church, known for helping to launch the Human Genome Project. Their research will appear in a forthcoming issue of the journal Science.

First, Bachelet and Douglas wondered if they could combine their respective expertise in immunology and building nanostructures to design a robot that would mimic the body's immune system. It would recognize infected cells and push their self-destruct buttons.

WATCH VIDEO: Nanotechnology promises to make our lives better.

Previous breakthroughs included a nanoscale cube with a lid debuted in 2009 that self-assembled in a process called "DNA origami." Adding DNA strands caused the box to open. But Douglas felt that making the box so it got delivered to the right cells would be too difficult. So would making the mechanisms to enter and reprogram the bad cells.

Then Bachelet suggested that they didn't have to reprogram anything. They just had to make a structure that could deliver the right antibodies to a cell's surface with a clear message: stop dividing.

"We could actually make an open-ended container and then all it would need to do is just turn itself inside out," Douglas said.

Their nano-robot is constructed from DNA in a clam shell shape held shut with a special DNA lock. That lock is designed to recognize certain kinds of cancer cells. When it encounters one, the robot springs open and exposes the antibody payload.

NEWS: How To Make Nano-Origami

So, in the fight against cancer, these nano-robots could be the equivalent of sending SEAL Team Six.

"Our ability to perform that 'surgical strike' with nanoscale devices will ultimately allow us to do so in a way that's safe for the patient," Douglas said.

In the lab, their nano-robot successfully blew up lymphoma and leukemia cells, leaving good cells alone. Doing one of these reactions typically requires 100 billion copies of the robot. In order to start testing their creation on animals, the Harvard postdocs will have to figure out how to scale up to trillions.

More science news from msnbc.com

Is it really worth researching romance?

Science editor Alan Boyle's blog: Will changing your name or your hair improve your love life? Maybe not, but research can point to more practical steps for life after Valentine's Day.

Spot color: Meet world's tiniest chameleon Songbirds trek record 9,000 miles to Africa Animal mummies among Egyptian treasures

Although the nano-robot works in a Petri dish, it will have to be redesigned for a trip through the bloodstream, Douglas said. Modifications are necessary to prevent the particle from getting cleared out by the kidneys or the liver before it has a chance to perform.

"My dream is for one of these devices to ultimately go through clinical trials and become an actual therapeutic that would be a novel treatment for some type of cancer," Douglas said.

Kurt Gothelf is a professor of chemistry at Aarhus University in Denmark, and the director of the Danish National Research Foundation's Center for DNA Nanotechnology. He and his colleagues made the self-assembling nanoscale DNA box with a lid in 2009.

"This is one of the things the field has needed, something to show that, hey, this can actually be useful" Gothelf said of the Harvard group's DNA nano-robot. Although their smart nanodevice isn't curing cancer yet, it does mark an important step along the way, he added.

"People have been talking a lot about robots that enter your body, and go to a place where something is wrong and fix it," Gothelf said. "This is the first example that this might come true one day."

© 2012 Discovery Channel

See more here:
DNA robots hunt down and kill cancer cells

Posted in DNA

DNA Robots Programmed to Kill Cancer Cells, Harvard Study Shows

By Elizabeth Lopatto - Thu Feb 16 19:00:00 GMT 2012

Enlarge image Robot Made from DNA May Help Deliver Drugs

Campbell Strong, Shawn Douglas & Gael McGill using Molecular Maya & cadnano via Bloomberg

Cell-targeting DNA nano-robots bearing antibody fragment payloads.

Cell-targeting DNA nano-robots bearing antibody fragment payloads. Source: Campbell Strong, Shawn Douglas & Gael McGill using Molecular Maya & cadnano via Bloomberg

Scientists have created a robot made entirely from DNA that can be instructed to find diseased cells in the body and deliver a payload to kill or reprogram them, according to a study from Harvard University.

The robot was constructed by folding DNA strands into a shape that looks roughly like a clamshell. The researchers programmed the nano-sized device to open in the presence of leukemia and lymphoma cells in a laboratory dish, where they delivered immune system antibodies that caused the cells to self-destruct, according to a report in the journal Science.

The next step will be to test the system in animals, tweaking the robot so that it can circulate longer in the blood to locate all cancer cells. The technology isn’t yet ready for commercial use, said Shawn Douglas, an author of the study.

“In diseases such as cancer we know if we can find every single last cell and kill or reprogram it, we can cure that disease,” said Douglas, a researcher at the Wyss Institute for Biologically Inspired Engineering at Harvard, in Boston. “A lot of our current therapies fall short.”

The idea is based on the behavior of the body’s immune cells, which recognize viruses or other invaders and attack them, Douglas said. The DNA nano-robots, with similar capabilities, may potentially lead to the development of new types of targeted cancer treatments that kill only abnormal cells, he said.

The robots don’t reproduce. They have to be constructed in a process that has gained traction since the idea of DNA nanotechnology was first suggested in 1982.

DNA is a material, shaped in the form of a revolving ladder, which carries the genetic information in our cells.

The double-sided strands have so-called sticky ends that allow them to be joined together with other DNA. Scientists, led by Nadrian Seeman, now head of the Department of Chemistry at New York University, have used those sticky ends to form DNA into lattices that can be shaped in various ways.

The latest research created a robot in a clamshell shape that’s held together with a “zipper” constructed of a special sequence of DNA, the report said. The zipper was programmed to release its grip when it recognized specific targets on a cell, allowing the robot to release its payload.

In the experiment, Douglas and his fellow scientists used the robot they constructed to deliver instructions encoded in antibodies to the cancer cells.

“It’s an important step forward in specific targeting,” said Milan Stojanovic, an assistant professor of experimental therapeutics at Columbia University in New York who wasn’t involved in the research, in an e-mail. “It looks very exciting.”

Besides cancer, the robots may also benefit people with autoimmune disease, Douglas said. One day, the robots might be used to find immune cells wrongly attacking the body and reprogram them, he said.

To contact the reporter on this story: Elizabeth Lopatto in New York at elopatto@bloomberg.net.

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net.

See original here:
DNA Robots Programmed to Kill Cancer Cells, Harvard Study Shows

Posted in DNA

MyHeritage Brings DNA Testing to the Global Community

PROVO, Utah & LONDON & TEL AVIV, Israel--(BUSINESS WIRE)--

MyHeritage, the most popular family network on the web, announced today the integration of DNA testing into its core family history offering. The move adds genetic genealogy to the company’s suite of tools for researching family history, used by millions of families around the world.

With more than 62 million registered users and 21 million family trees, MyHeritage has become the trusted home on the web for families wishing to explore their family history, share memories and stay connected. With the new biological layer added to the MyHeritage experience, users can now enjoy a service combining science, intuitive web features and social networking for discovering and sharing their family legacy.

“DNA testing provides a fascinating new way to discover one’s origins and find previously unknown relatives”, said MyHeritage Founder and CEO Gilad Japhet. “Offering the highest quality DNA tests to our tens of millions of users around the world in 38 languages, and providing DNA matches with hundreds of thousands of people who have already had their DNA tested, significantly advances our mission of bringing family history to the masses. By combining DNA with our innovative Smart Matching™ technology, families will be closer than ever before to constructing a more complete picture of their history”.

DNA is the hereditary material in humans and almost all other organisms. By purchasing a simple cheek-swab DNA test, users can now use information contained in their DNA to find present-day relatives who share a common ancestor up to many hundreds of years ago. A DNA test can also reveal ethnic origins such as Native American, African or Jewish descent on paternal or maternal lines, as well as uncover ancestral information for those who were adopted. While DNA tests can break through brick walls in family history research by revealing biological relations, MyHeritage’s flagship Smart Matching™ technology then steps in to help piece together the paper trail by uncovering how the family trees of related people actually connect. In addition, people with the same paternal surname can get together via MyHeritage to see if they’re related by DNA.

MyHeritage is introducing today a wide range of DNA tests to meet different research objectives and budgets, with special discounted prices for MyHeritage subscribers starting from as low as $84. Users can identify the deep ancestral origins of their direct paternal line (Y-DNA), of their direct maternal line (mtDNA), find relatives across all lines via autosomal DNA (Family Finder), receive a percentage breakdown of their ethnic roots and confirm or disprove whether someone is a close relative. View the full list of the DNA kits on MyHeritage and a list of Frequently Asked Questions about DNA tests on MyHeritage.

For the analysis of users’ DNA tests and the DNA matching, MyHeritage is working with long-time partner and global leader in genealogy DNA, Family Tree DNA. Pioneers of genetic genealogy and with a state-of-the-art laboratory, Family Tree DNA has established the world’s largest DNA database for genealogy and is well known for its work with National Geographic on the Genographic Project. All information is kept strictly confidential and is never shared.

Bennett Greenspan, President and CEO of Family Tree DNA said “We’re proud to work with MyHeritage to bring DNA testing to a much wider, global audience. The phenomenal size and reach of the global MyHeritage family network will create new horizons in collecting DNA data, helping many more people discover their ancestral origins”.

About MyHeritage

MyHeritage is the most popular family network on the web. Millions of families around the world enjoy having a private and free place for their families to keep in touch and to showcase their roots. MyHeritage’s Smart Matching™ technology empowers users with an exciting and innovative way to find relatives and explore their family history. Following the November 2011 acquisition of FamilyLink in Provo, Utah, MyHeritage offers billions of historical records through its website WorldVitalRecords.com. With all family information stored in a secure site, MyHeritage is the ideal place to share family photos and preserve special family memories. The site is available in 38 languages. So far more than 62 million people have signed up to MyHeritage. The company is backed by Accel Partners and Index Ventures, the investors of Facebook and Skype. For more information visit http://www.myheritage.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50170450&lang=en

MULTIMEDIA AVAILABLE:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50170450&lang=en

View original post here:
MyHeritage Brings DNA Testing to the Global Community

Posted in DNA

New Faculty of 1000 Application Identifies the Best Research in Biology and Medicine Covered in Elsevier's SciVerse

LONDON, UNITED KINGDOM--(Marketwire -02/16/12)- Faculty of 1000 (F1000), an online service that selects and evaluates articles based on the opinions of global leaders in biology and medicine, today announced the launch of a new application that helps researchers explore the scientific content in biology and medicine included in Elsevier's SciVerse platform.

"The Faculty of 1000 app (http://www.applications.sciverse.com/action/appDetail/298954) now available in SciVerse Applications allows researchers to tap into the collective knowledge of our 10,000 experts to determine which research is essential reading and to find relevant information efficiently," said Jane Hunter, Managing Director, F1000. "With the continued volume growth of published research, the guidance of the F1000 faculty becomes even more essential for researchers."

Once a SciVerse user adds the app, the articles that have been highlighted by the F1000 faculty will display a badge that, when clicked, brings the user to the F1000 evaluation.

"The F1000 application offers another option for researchers to filter information that is relevant to their domain," said Rafael Sidi, Vice President, Application Marketplace and Developer Network at Elsevier. "We look forward to continued collaborations with developers in creating solutions that enhance research efficiency."

SciVerse Applications and the Developer Network provide opportunities for researchers and librarians to collaborate with developers in creating and promoting new applications that improve research workflows. The Developer Network features a growing community of application developers that gain potential recognition, prestige and revenue through their contributions to SciVerse Applications.

For more information, visit http://f1000.com.

About Faculty of 1000

Faculty of 1000 is a unique online service that selects and evaluates important articles based on the opinions of global leaders in biology and medicine. F1000's distinguished international Faculty identify key articles across these fields, providing a rapidly updated, authoritative guide to the life science literature that matters. Find out more at http://f1000.com.

About the Elsevier SciVerse Suite

The SciVerse® suite of search and discovery offerings provides the global research community access to a constantly expanding universe of content and solutions which can now be accessed in one platform. The suite currently includes SciVerse ScienceDirect®, the world's largest source of peer-reviewed content containing more than 10 million articles, and SciVerse Scopus®, an abstract and citation database containing 41 million records, 70% with abstracts and nearly 19,500 titles from 5,000 publishers worldwide. The platform also includes SciVerse Hub which enables researchers to perform a single search across all of the major peer-reviewed publishers as well as targeted web content with results ranked by relevancy and without duplication. Applications and Developer Network allow the scientific community to build, find and use applications that enhance the SciVerse research experience.

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Read more:
New Faculty of 1000 Application Identifies the Best Research in Biology and Medicine Covered in Elsevier's SciVerse

Graduation exam changing to biology

March will the last time high school students will have to pass a science test in order to receive a diploma.

But, students shouldn't expect to get off the hook when it comes to science in graduation testing. Over the last few years, the state has gradually transitioned the science test to a biology test, said Larry Hooks, Fort Payne City schools administrative assistant to the superintendent.

"We've been giving a biology and a science exam for the last two years," Hooks said. "It's been gradually transitioned to a biology test. This March will be the last time the science test is given. There is a little more rigor to the biology test. It's a little tougher test."

The change from science to biology was mandated by the Alabama Department of Education. The difference in terminology of science and biology may seem a little confusing. But, the biology test encompasses the majority of the objectives for the science test and expands on those objectives.

For example, the science objectives included questions on tracing matter and energy transfer, the periodic table, identifying physical and chemical changes, differentiating the characteristics of plants, animals and ecosystems and Newton's three laws of motion.

The biology objectives are defined in 16 different categories that cover a wide range of study. Students will be required to use lab equipment for experiments, understanding homeostasis, photosynthesis, biological division and the ability to identify cells, organ systems, populations, communities and ecosystems. Students will also be tested on Mendel's laws, DNA, RNA, different types of plants, classify animals, describe animal adaptations and understanding how energy flows through the food chains.

In order to receive a diploma, students must pass a graduation test that covers five fields of study. Hooks said the students are tested in math, social studies, language, reading and, currently, science and biology. After the graduation exams are administered in March, the science test will be replaced by the biology test.

Underclassmen, however, will have an opportunity to grandfather in and pass the science test before the transition to biology is complete. In March, juniors will be able to take the test, as well as sophomores, who take the test as a pre-graduation test. Ninth-graders currently have an opportunity to pass what is termed an Early Opportunity Test in math or biology.

However, Hooks said, the freshmen students must first pass biology or algebra before they can take the Early Opportunity Test.

"Tenth-graders will have the opportunity to take the test as a pre-graduation test," Hooks said. "It won't be counted against them if they fail the test, but it will count toward their graduation requirements if they pass the test.

"Students have to pass all areas of the graduation exam in order to get a diploma. They get the requirements in the ninth grade, so they know what they have to pass."

DeKalb County schools will give the last science test March 21 at 8 a.m.

© 2012 times-journal.com. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Read more:
Graduation exam changing to biology

New F1000 app identifies top research in biology and medicine covered in Elsevier's SciVerse

Public release date: 16-Feb-2012
[ | E-mail | Share ]

Contact: Eleanor Howell
press@f1000.com
44-020-763-19129
Faculty of 1000: Biology and Medicine

Faculty of 1000 (F1000) http://f1000.com, an online service that selects and evaluates articles based on the opinions of global leaders in biology and medicine, today announced the launch of a new application that helps researchers explore the scientific content in biology and medicine included in Elsevier's SciVerse platform.

"The Faculty of 1000 app (http://www.applications.sciverse.com/action/appDetail/298954) now available in SciVerse Applications allows researchers to tap into the collective knowledge of our 10,000 experts to determine which research is essential reading and to find relevant information efficiently," said Jane Hunter, Managing Director, F1000. "With the continued volume growth of published research, the guidance of the F1000 faculty becomes even more essential for researchers."

Once a SciVerse user adds the app, the articles that have been highlighted by the F1000 faculty will display a badge that, when clicked, brings the user to the F1000 evaluation.

"The F1000 application offers another option for researchers to filter information that is relevant to their domain," said Rafael Sidi, Vice President, Application Marketplace and Developer Network at Elsevier. "We look forward to continued collaborations with developers in creating solutions that enhance research efficiency."

SciVerse Applications and the Developer Network provide opportunities for researchers and librarians to collaborate with developers in creating and promoting new applications that improve research workflows. The Developer Network features a growing community of application developers that gain potential recognition, prestige and revenue through their contributions to SciVerse Applications.

###

To find out more about Faculty of 1000, please contact Eleanor Howell on 44-20-7631-9129 or email press@f1000.com. For more information, visit http://f1000.com.


[ | E-mail | Share ]

 

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Read the original post:
New F1000 app identifies top research in biology and medicine covered in Elsevier's SciVerse

Teacher ratio condition for PG courses

Muzaffarpur, Feb. 16: Health minister Ashwini Kumar Choubey has said the state government was exploring the possibilities to start postgraduate courses in disciplines that have sufficient teacher strength at Sri Krishna Medical College and Hospital (SKMCH).

Choubey, who reviewed the ongoing health schemes with senior officials of Tirhut and Saran divisions last night, said the government was not averse to postgraduate courses, but SKMCH would be allowed to start courses in departments that have sufficient teachers.

In 2010, the Centre had allowed SKMCH to start postgraduate courses in 12 subjects. It provided Rs 6 crore to SKMCH for infrastructure development before introducing the postgraduate courses. But as things stand now, the heads of the departments of those courses, in which the postgraduate classes were scheduled to start, sat over the proposal allegedly to scuttle the move.

SKMCH principal D.K. Sinha had complained about the "lethargic approach" of the heads of various departments and sought immediate intervention of the government.

Choubey discussed the issue at length with the superintendent of SKMCH, G.K. Thakur, Sinha and other senior doctors. The minister said: "SKMCH would soon start postgraduate classes in medicine, surgery, preventive and social medicine, biochemistry, microbiology, pharmacology and pathology." The minister admitted that SKMCH was in a tight spot to start postgraduate courses for want of teachers. On the encephalitis breakout in Muzaffarpur and Gaya, the health minister said the state is leaving no stone unturned to control its surge and is prepared to prevent it.

Read the original here:
Teacher ratio condition for PG courses

NSF Grant Challenges Traditional Teaching Strategies in Chemistry Labs

Newswise — Two South Dakota State University professors want to change the way students learn about chemistry. That’s the goal of a two-year, $200,000 National Science Foundation grant awarded to associate professors of chemistry and biochemistry, David Cartrette and Matt Miller.

“Students are typically given a recipe and don’t always think about how to change it to make a better experiment,” said Miller. “It’s just a verification process that we hope to change through introducing collaboration between first- and second-year chemistry students.”

The nationally funded laboratory curriculum the professors will write is built on three guiding principles. First, students need to be trained in lab techniques with scientific instruments used by most chemists in everyday work. Second, students need multiple opportunities to use these techniques and instruments to answer real-world questions related to science. Finally, experience shows students need to understand that successful, original research and experimentation is not a solo operation.

The lab teaching model developed by Miller and Cartrette brings together a hierarchical system of research that uses an apprentice/mentor model. Their teaching strategies mimic that model by having two different levels of undergraduate classes work together to create a community of learning much like faculty research that engages graduate students.

The interaction of the two class levels intends to simulate what happens when someone starts a new job. The newly hired person is typically trained by someone more experienced with the job and its responsibilities. The second-year students act as trainers, while the first-year students act as trainees. The goal of this interaction, said the professors, is to develop a team environment where students teach and learn from each other.

“The focus is on creativity and collaboration,” said Cartrette. “It’s taking the abstract and making it applicable to real world issues — taking knowledge and applying it to real world problems.”

Students in these lab courses begin their studies in a very traditional sense; they master the techniques used in a chemistry lab. As they progress through the curriculum, they use these techniques to address real problems for which no answer is known. The approach quickly moves students toward more independent thinking and motivates them to perform original experiments. Working collaboratively, the professors said, lets students experience what most research students experience as they begin the research process.

The professors said such cooperative environments help create greater interest in research as students learn about the social aspects of working with others, not unlike a professional research laboratory that includes a wide range of scientists.

Cartrette and Miller’s efforts address the call for science education enhancement at the state and national levels. In February 2012, President Obama received an executive report that recommended to “advocate and provide support for replacing standard laboratory courses with discovery based research courses.”

At the state level, the South Dakota Legislature is proposing increased funding for math and science teachers in public schools.

The NSF-funded curriculum model also addresses upcoming changes in medical school admissions procedures; future editions of the medical school admissions exam, or MCAT, will focus on performance outcomes, as opposed to factual knowledge recall. Miller and Cartrette’s project, funded last summer, they said, addresses these proposed changes.

“In a way, we foresaw these changes and acted to modify our curriculum to address them,” Cartrette said.

The NSF grant will fund the advanced instrumentation needed for the project. Associate Professor Kenneth Emo, from the Department of Teaching, Learning and Leadership, assisted by chemistry and biochemistry graduate student Jaclyn Nielsen, will evaluate the educational outcomes of the project.

Additionally, presentations made by Cartrette and Miller at national workshops will describe how students learn through collaborative interactions in a lab environment. The two will also write journal articles on the process and develop teacher-training workshops that can be replicated in other educational settings, at both universities and high schools.

Both Miller and Cartrette’s teaching experience has earned them awards for their instruction. Both have been awarded the Edward Patrick Hogan Award for Excellence in Teaching at SDSU to recognize outstanding achievement in undergraduate instruction. Miller has also received the Elaine and Leo Spinar Chemistry & Biochemistry Teaching Award from the Department of Chemistry and Biochemistry.

About South Dakota State University

Founded in 1881, South Dakota State University is the state’s Morrill Act land-grant institution as well as its largest, most comprehensive school of higher education. SDSU confers degrees from eight different colleges representing more than 175 majors, minors and specializations. The institution also offers 29 master’s degree programs, 12 Ph.D. and two professional programs.

The work of the university is carried out on a residential campus in Brookings, at sites in Sioux Falls, Pierre and Rapid City, and through Cooperative Extension offices and Agricultural Experiment Station research sites across the state.

Comment/Share

Read more from the original source:
NSF Grant Challenges Traditional Teaching Strategies in Chemistry Labs

Biochemistry professor receives patent

Posted: Wednesday, February 15, 2012 9:17 pm | Updated: 1:41 pm, Thu Feb 16, 2012.

One University professor is now teaching students with a new patent under his name.

Professor of biochemistry Dr. Rafiq Islam invented a method to detect sugar and silver nanoparticles by using a microwave.

According to the leading Life Science and high technology company, Sigma-Aldrich of St. Louis, silver nanoparticles are being incorporated into products that range from photovoltaic to biological and chemical sensors.

"I don't know how my invention will change people's lives," Islam admits. "But by simplifying procedure, it might be helpful for components they are making now."

Islam said he has been working on the invention since 2006. He believes it is an inexpensive task that other scientists and biochemists can use.

Although it took a few years to develop the invention, Islam said the process to receiving his patent was surprisingly simple.

Associate professor of organic chemistry at the University Dr. Ahmed Mlakawi watched Islam as he progressed with his soon-to-be patent. Mlakawi said a number of students have been asking him about Islam's newest invention.

"It's exciting and inspiring to those students who have been asking me about it," Mlakawi said.

Islam said he encourages students at the University to chase their dreams just like he did.

"We have a good number of resources in our department, and that should inspire them (students)," Islam said.

Islam is proud of his achievement, but said his invention won't stop with a patent.

Although his project is relatively new to him because it's in a field other than the one he specializes in, Islam enjoys the field of bioscience more.

"But I like to combine those two," Islam said. "I know I'm in biochemistry, but I want to try to move on and progress in nanochemistry as well."

Posted in News, Campus on Wednesday, February 15, 2012 9:17 pm. Updated: 1:41 pm.

Original post:
Biochemistry professor receives patent